Thomas H.R. Carlsen, Jannie Pedersen, Jannick C. Prentoe, Erick Giang, Zhen‐Yong Keck, Lotte S. Mikkelsen, Mansun Law, Steven K.H. Foung, Jens Bukh – 8 July 2014 – Human monoclonal antibodies (HMAbs) with neutralizing capabilities constitute potential immune‐based treatments or prophylaxis against hepatitis C virus (HCV). However, lack of cell culture‐derived HCV (HCVcc) harboring authentic envelope proteins (E1/E2) has hindered neutralization investigations across genotypes, subtypes, and isolates.

8 July 2014

Jacqueline G. O'Leary, S. Michelle Shiller, Christopher Bellamy, Michael A. Nalesnik, Hugo Kaneku, Linda W. Jennings, Kumiko Isse, Paul I. Terasaki, Göran B. Klintmalm, Anthony J. Demetris – 6 July 2014 – Acute antibody‐mediated rejection (AMR) occurs in a small minority of sensitized liver transplant recipients. Although histopathological characteristics have been described, specific features that could be used (1) to make a generalizable scoring system and (2) to trigger a more in‐depth analysis are needed to screen for this rare but important finding.

Liping Chen, Geng Chen, Yibin Guo, Lei Liu, Li Xiao, Wenmei Fan, Bingyi Shi, Yeyong Qian – 5 July 2014 – Biliary fibrosis is a major complication after donation after cardiac death (DCD) liver transplantation. In this process, the roles of serotonin [5‐hydroxytryptamine (5‐HT)] and the 5‐HT2A receptor subtype are still unknown.

Susan Holtzman, Hance A. Clarke, Stuart A. McCluskey, Kara Turcotte, David Grant, Joel Katz – 5 July 2014 – Despite its prominence as a concern among potential surgical candidates, there is little information in the literature regarding the short‐ and long‐term pain experience after living liver donation. We undertook a prospective study to examine (1) the nature and incidence of acute and chronic pain after living donor hepatectomy and (2) the factors associated with an increased or decreased risk of adverse pain outcomes.

Jasmine Kouz, Catherine Vincent, Aaron Leong, Marc Dorais, Agnès Räkel – 5 July 2014 – Posttransplant weight gain is common after orthotopic liver transplantation. We sought to determine the extent of weight gain at 5 years after transplantation in patients with nonalcoholic fatty liver disease (NAFLD) cirrhosis versus patients with other types of cirrhosis (non‐NAFLD). We studied 126 liver transplants performed between 2005 and 2007 at Saint Luc Hospital, University of Montreal. Seventeen of the 126 patients (13.5%) had NAFLD cirrhosis.

Aparna Goel, Neil Mehta, Jennifer Guy, Nicholas Fidelman, Francis Yao, John Roberts, Norah Terrault – 5 July 2014 – Liver transplantation (LT) is the treatment of choice for patients with cirrhosis and hepatocellular carcinoma (HCC) not amenable to resection. Locoregional therapies for HCC are often used to reduce tumor burden, bridge patients to LT, and down‐stage HCC so that patients are eligible for LT. We hypothesized that prior endovascular antitumor therapy may increase the risk of hepatic artery (HA) and biliary complications after LT.

Emily Rothbaum Perito, Philip Rosenthal – 5 July 2014

Lisa B. VanWagner, Brittany Lapin, Josh Levitsky, John T. Wilkins, Michael M. Abecassis, Anton I. Skaro, Donald M. Lloyd‐Jones – 5 July 2014 – Cardiovascular disease (CVD) contributes to excessive long‐term mortality after liver transplantation (LT); however, little is known about early postoperative CVD mortality in the current era. In addition, there is no model for predicting early postoperative CVD mortality across centers.

Valerie Sapp, Leah Gaffney, Steven F. EauClaire, Randolph P. Matthews – 4 July 2014 – Nonalcoholic fatty liver disease (NAFLD), the accumulation of lipid within hepatocytes, is increasing in prevalence. Increasing fructose consumption correlates with this increased prevalence, and rodent studies directly support fructose leading to NAFLD. The mechanisms of NAFLD and in particular fructose‐induced lipid accumulation remain unclear, although there is evidence for a role for endoplasmic reticulum (ER) stress and oxidative stress.